U.S. markets close in 1 hour 13 minutes
  • S&P 500

    3,705.42
    +58.13 (+1.59%)
     
  • Dow 30

    29,585.77
    +450.78 (+1.55%)
     
  • Nasdaq

    11,001.67
    +172.17 (+1.59%)
     
  • Russell 2000

    1,711.44
    +48.94 (+2.94%)
     
  • Crude Oil

    82.22
    +3.72 (+4.74%)
     
  • Gold

    1,668.50
    +32.30 (+1.97%)
     
  • Silver

    18.91
    +0.57 (+3.12%)
     
  • EUR/USD

    0.9743
    +0.0145 (+1.51%)
     
  • 10-Yr Bond

    3.7450
    -0.2190 (-5.52%)
     
  • GBP/USD

    1.0888
    +0.0157 (+1.46%)
     
  • USD/JPY

    144.0700
    -0.7210 (-0.50%)
     
  • BTC-USD

    19,503.38
    +439.75 (+2.31%)
     
  • CMC Crypto 200

    444.51
    +15.73 (+3.67%)
     
  • FTSE 100

    7,005.39
    +20.80 (+0.30%)
     
  • Nikkei 225

    26,173.98
    -397.89 (-1.50%)
     

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

·2 min read

CAMBRIDGE, Mass., September 02, 2022--(BUSINESS WIRE)--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 8,200 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The awards were granted on August 30, 2022. One award vests as to one-quarter of the shares on March 31, 2023 and as to an additional one-quarter of the shares at the end of each successive year thereafter, and the other award vests as to one-quarter of the shares on August 31, 2023 and as to an additional one-quarter of the shares at the end of each successive year thereafter, in each case subject to the employee’s continued service with Syros. Both awards are subject to the terms and conditions of a restricted stock unit agreement covering the award and Syros’ 2022 Inducement Stock Incentive Plan.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220902005008/en/

Contacts

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com